Rhenman & Partners Asset Management’s Harmony Biosciences HRMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-81,474
| Closed | -$2.67M | – | 90 |
|
|
2023
Q3 | $2.67M | Sell |
81,474
-128,526
| -61% | -$4.21M | 0.29% | 68 |
|
|
2023
Q2 | $7.39M | Buy |
210,000
+40,000
| +24% | +$1.41M | 0.78% | 43 |
|
|
2023
Q1 | $5.56M | Sell |
170,000
-70,000
| -29% | -$2.29M | 0.61% | 55 |
|
|
2022
Q4 | $13.2M | Buy |
240,000
+3,000
| +1% | +$165K | 1.38% | 31 |
|
|
2022
Q3 | $12.3M | Sell |
237,000
-23,000
| -9% | -$1.2M | 1.29% | 31 |
|
|
2022
Q2 | $12.7M | Sell |
260,000
-8,244
| -3% | -$402K | 1.44% | 28 |
|
|
2022
Q1 | $13.1M | Buy |
268,244
+48,244
| +22% | +$2.35M | 1.29% | 32 |
|
|
2021
Q4 | $9.53M | Buy |
220,000
+15,124
| +7% | +$655K | 0.63% | 56 |
|
|
2021
Q3 | $7.85M | Buy |
204,876
+104,876
| +105% | +$4.02M | 0.55% | 56 |
|
|
2021
Q2 | $2.82M | Buy |
+100,000
| New | +$2.82M | 0.19% | 90 |
|